Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06779630 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

A NA study of Coronary Artery Disease, sponsored by Teleflex.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
15
Study locations

NCT06779630 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Teleflex. The registered enrollment target is 150 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower). The trial reports 15 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06779630, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Teleflex.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
15
Study locations

Study Summary

The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm. Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patients enrolled outside of the United States will be followed through 5 years post index procedure with additional follow-up visits at 3 and 5 years post index procedure.

Conditions Studied

Coronary Artery Disease

Interventions

  • DEVICE Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System

Study Locations (15)

Texas

  • Baylor Scott & White The Heart Hospital - Dallas - Dallas
  • Ascension Texas Cardiovascular - Kyle

California

  • John Muir Medical Center - Concord

Kansas

  • Ascension Via Christi Hospitals Wichita - Wichita

New York

  • Columbia University Irving Medical Center/New York Presbyterian Hospital - New York

West Virginia

  • Charleston Area Medical Center - Charleston

Styria

  • Klinische Abteilung für Kardiologie, Medizinische Universität Graz - Graz

Vienna

  • Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie, Medizinische Universität Wien - Vienna

Provence-Alpes-Côte d'Azur Region

  • Institut Arnault Tzanck - Saint-Laurent-du-Var

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-07-18
Est. Completion 2031-09
Phase NA

Sponsor

Teleflex

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06779630

The ClinicalTrials.gov registry entry for NCT06779630 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower). The listed sponsor is Teleflex, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System is the first listed.

NCT06779630 reports 15 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Kansas.

Frequently Asked Questions

What is clinical trial NCT06779630 about?

NCT06779630 is a clinical study titled "Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions". The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel d...

What is the current status of trial NCT06779630?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-07-18. Estimated completion is 2031-09.

What conditions does trial NCT06779630 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT06779630?

The interventions under investigation include: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System (DEVICE).

Who is sponsoring clinical trial NCT06779630?

This trial is sponsored by Teleflex, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06779630 being conducted?

This trial has 15 study locations across California, Kansas, New York, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.